Colin Berry, MB, ChB, FACC

Professional Bio:

Current position Professor Colin Berry holds a Chair in Cardiology and Imaging in the University of Glasgow. He is a Fellow of the Royal College of Physicians and Surgeons of Glasgow, the Royal College of Physicians of Edinburgh, the American College of Cardiology and the European Society of Cardiology. He is Director of Research and Development in the Golden Jubilee National Hospital. He is also a Consultant Cardiologist in this hospital and in the Queen Elizabeth University Hospital in Glasgow. His subspecialty interests are Imaging and Interventional Cardiology. Background Professor Berry undertook undergraduate medical studies at the University of Glasgow (1987-1993) and completed an intercalated science degree (Maîtrise, Physiology) at the University of Paris (1989-1990). He was awarded a PhD at the University of Glasgow (2002) in Cardiovascular Science and his studies were supported by a Medical Research Council Clinical Training Fellowship. Professor Berry trained in Cardiology and Internal Medicine (2001-2006) first in Glasgow and then at the Montreal Heart Institute (2005-2006). Whilst in Montreal, he worked in Jean-Claude Tardif's Atherosclerosis Research Group and used coronary imaging techniques to study stem cells and coronary artery disease. His research in Montreal was supported by a British Heart Foundation International Fellowship and an International Exchange Award from the Royal Society of Edinburgh. When in Montreal, he became the first British clinician to participate in transcatheter aortic valve replacement. He then undertook post-doctoral studies (2007-2009) in advanced cardiovascular imaging in Andrew Arai’s group at the National Heart, Lung and Blood Institute, US National Institutes of Health, Bethesda, MD. This appointment was supported by a Lord Kelvin Adam Smith Fellowship from the University of Glasgow. In 2009, Professor Berry secured a Senior Clinical Fellowship from the Scottish Funding Council. In 2014, Professor Berry was awarded the Marshall Research Excellence Prize from the British Society of Cardiovascular Research. Currently, he is the Treasurer of the British Society of Cardiovascular Magnetic Resonance and the Chair of the Clinical Trials Committee of the Society of Cardiovascular Magnetic Resonance. He is the recent past Chair of the British Society of Cardiovascular Research. Leader: Cardiac Research His heart research focuses on two areas 1) injury and repair pathways in heart attack and heart failure, and 2) small blood vessel function in the heart. In the heart attack research, his group seeks to better understand the nature of heart muscle injury, including causes, consequences, and health outcomes in the longer term. His research described the natural history of heart muscle bleeding after a heart attack. The research uses novel medical technologies such as diagnostic guidewires that can measure blood pressure and resistance inside blood vessels within the heart, and heart imaging with MRI. Current and future studies are aimed to identify new treatments, such as in the T-TIME study, which may help patients who have had a heart attack. His group are also working with mathematicians and statisticians to develop ‘patient-specific’ computed heart models from heart scans in order to better predict clinical outcome and response to treatment. The research into small blood vessel function in the heart aims to assess the causes and consequences of small blood vessel problems in the heart, and how such problems could be treated. Potentially, small vessel problems could be an important and under-recognised cause of angina. This research includes studies such as COR-MED and CorMicA and is supported by the British Heart Foundation Centre of Research Excellence award. His research has been supported by the British Heart Foundation, Chest Heart and Stroke Scotland, Chief Scientist Office, Engineering and Physical Sciences Research Council, Medical Research Scotland, Scottish Funding Council, and Wellcome Trust.

General Statement of Disclosure:


View Full Disclosure